RADIOTHERAPY AS THE PRIMARY AND PALLIATIVE TREATMENT FOR PATIENTS AGED 75 AND OVER WITH LOCALLY ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER: ANALYSIS OF 45 CASES WITH A REVIEW OF THE LITERATURE

Basit Öğe Kaydı
dc.authoridFayda, Merdan/0000-0002-2800-5327;
dc.authorwosidFayda, Merdan/AAF-7370-2019
dc.authorwosidFayda, Merdan/F-5092-2012
dc.authorwosidOral, Ethem Nezih/AAE-2018-2020
dc.authorwosidKizir, Ahmet/AAS-5306-2020
dc.contributor.authorAksu, Gorkem
dc.contributor.authorFayda, Merdan
dc.contributor.authorSaynak, Mert
dc.contributor.authorSaglamer, Esra Kaytan
dc.contributor.authorOral, Ethem Nezih
dc.contributor.authorKizir, Ahmet
dc.contributor.authorKaradeniz, Ahmet
dc.date.accessioned2024-06-12T11:00:10Z
dc.date.available2024-06-12T11:00:10Z
dc.date.issued2008
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAim: To evaluate the prognostic factors and treatment results of Turkish patients aged 75 and over with locally advanced and metastatic non-small cell lung cancer (NSCLC). Patients and Methods: Forty-five patients >= 75 years were evaluated. The median age was 78 (75-93). Thirty-four patients (75%) had stage IIIB and 11 patients had stage IV disease (25%). Fourteen patients (41%) with stage IIIB disease were treated with curative radiotherapy (RT), 18 patients (52%) with palliative RT and 2 patients (5%) were treated with only chemotherapy (CT). Results: The one-year survival rate was 37%. The overall median survival was 12.7 months in stage IIIB and 7.67 months in stage IV. In univariate analysis, advanced stage (p=0.0006), performance status (p=0.056), absence of radiotherapy (p=0.0008) and weight loss (p=0.0053) adversely affected survival. In multivariate analysis only stage IV was found to be a statistically significant independent poor prognostic factor (p=0.0025 HR=0.2760 (0.12-0.60) 95% confidence interval). Conclusion: In Turkish patients, with NSCLC, aged 75 or over, stage IV disease was associated with poor prognosis. The higher radiotherapy doses did not improve survival in patients with stage IIIB disease and the prognosis with only radiotherapy is similar to the results of chemoradiation in the literature in this age group.en_US
dc.identifier.endpage20en_US
dc.identifier.issn1309-9469
dc.identifier.issue1en_US
dc.identifier.startpage11en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20723
dc.identifier.volume21en_US
dc.identifier.wosWOS:000219977400003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherMarmara Univ, Fac Medicineen_US
dc.relation.ispartofMarmara Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectElderlyen_US
dc.subjectLung Canceren_US
dc.subjectPrognostic Factorsen_US
dc.subjectRadiotherapyen_US
dc.subjectChemotherapyen_US
dc.titleRADIOTHERAPY AS THE PRIMARY AND PALLIATIVE TREATMENT FOR PATIENTS AGED 75 AND OVER WITH LOCALLY ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER: ANALYSIS OF 45 CASES WITH A REVIEW OF THE LITERATUREen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu